Urinary 20-hydroxyeicosatetraenoic acid is associated with endothelial dysfunction in humans

Circulation

Volumn 110, Issue 4, 2004, Pages 438-443

  Ward, Natalie C ^a   Rivera, Jennifer ^a   Hodgson, Jonathan ^a   Puddey, Ian B ^a   Beilin, Lawrie J ^a   Falck, John R ^b   Croft, Kevin D ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Blood pressure; Endothelium; Fatty acids; Hypertension

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ALKANE 1 MONOOXYGENASE; ARACHIDONIC ACID; CYTOCHROME P450; GLYCERYL TRINITRATE; NITRIC OXIDE; SODIUM; UNCLASSIFIED DRUG;

20 HYDROXYEICOSATETRAENOIC ACID URINE LEVEL; ADULT; AGE; ARTICLE; ATTENUATION; BLOOD FLOW; BLOOD PRESSURE; BODY MASS; BRACHIAL ARTERY; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG URINE LEVEL; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HYPERTENSION; IN VIVO STUDY; MALE; MASS SPECTROMETRY; MULTIPLE REGRESSION; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEX DIFFERENCE; SODIUM EXCRETION; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

BODY MASS INDEX; BRACHIAL ARTERY; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; HYPERTENSION; MALE; MODELS, CARDIOVASCULAR; VASODILATION;

EID: 3342875746     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000136808.72912.D9     Document Type: Article

References (34)

1. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev. 2002;82:131-185.
2. McGiff JC, Quilley J. 20-Hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids and blood pressure. Curr Opin Nephrol Hypertens. 2001; 10:231-237.
3. Imig JD, Zou AP, Stec DE, et al. Formation and actions of 20-hydroxyeicosatetraenoic acid in rat renal arterioles. Am J Physiol. 1996;270: R217-R227.
4. Roman RJ. Does 20-HETE mediate the cGMP independent actions of NO? High Blood Pressure Res Newsletter. 1999;Fall:20-22.
5. Hercule HC, Oyekan AO. Cytochrome P450 omega/omega-1 hydroxylase-derived eicosanoids contribute to endothelin(A) and endothelin(B) receptor-mediated vasoconstriction to endothelin-1 in the rat preglomerular arteriole. J Pharmacol Exp Ther. 2000;292:1153-1160.
6. Croft KD, McGiff JC, Sanchez-Mendoza A, et al. Angiotensin II releases 20-HETE from rat renal microvessels. Am J Physiol. 2000;279: F544-F551.
7. Chu ZM, Croft KD, Kingsbury DA, et al. Cytochrome P450 metabolites of arachidonic acid may be important mediators in angiotensin II-induced vasoconstriction in the rat mesentery in vivo. Clin Sci. 2000;98:277-282.
8. + channel activity and vascular tone in renal arterioles. Circ Res. 1998;83:1069-1079.
9. Alonso-Galicia M, Drummond HA, Reddy KK, et al. Inhibition of 20-HETE production contributes to the vascular responses to nitric oxide. Hypertension. 1997;29:320-325.
10. Celermajer DS, Sorensen KE, Bull C, et al. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol. 1994;24: 1468-1474.
11. Taddei S, Virdis A, Ghiadoni L, et al. Endothelial dysfunction in hypertension. J Cardiovasc Pharmacol. 2001;38(suppl 2):S11-S14.
12. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111-1115.
13. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol. 1995;26:1235-1241.
14. Vita JA, Keaney JF Jr. Endothelial function: a barometer for cardiovascular risk? Circulation. 2002;106:640-642.
15. Fleming I. Cytochrome p450 and vascular homeostasis. Circ Res. 2001; 89:753-762.
16. + channels. Circulation. 2001;103:1992-1998.
17. Levere RD, Martasek P, Escalante B, et al. Effect of heme arginate administration on blood pressure in spontaneously hypertensive rats. J Clin Invest. 1990;86:213-219.
18. Sacerdoti D, Balazy M, Angeli P, et al. Eicosanoid excretion in hepatic cirrhosis. J Clin Invest. 1997;100:1264-1270.
19. Su P, Kaushal KM, Kroetz DL. Inhibition of renal arachidonic acid omega-hydroxylase activity with ABT reduces blood pressure in the SHR. Am J Physiol. 1998;275:R426-R438.
20. Wang MH, Zhang F, Marji J. et al. CYP4A1 antisense oligonucleotide reduces mesenteric vascular reactivity and blood pressure in SHR. Am J Physiol. 2001;280:R255-R261.
21. Holla VR, Adas F, Imig JD, et al. Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. Proc Natl Acad Sci USA. 2001;98:5211-5216.
22. Laffer CL, Laniado-Schwartzman M, Wang M, et al. Differential regulation of natriuresis by 20-hydroxyeicosatetraenoic acid in human salt-sensitive versus salt-resistant hypertension. Circulation. 2003;107: 574-578.
23. Prakash C, Zhang JY, Falck JR, et al. 20-Hydroxyeicosatetraenoic acid is excreted as a glucuronide conjugate in human urine. Biochem Biophys Res Commun. 1992;185:728-733.
24. Dogra G, Rich L, Stanton K, et al. Endothelium-dependent and independent vasodilation studies at normoglycaemia in type I diabetes mellitus with and without microalbuminuria. Diabetolagia. 2001;44: 593-601.
25. Ghiadoni L, Magagna A, Versari D, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension. 2003; 41:1281-1286.
26. Rivera J, Ward N, Hodgson J, et al. Measurement of 20-HETE in human urine using gas chromatography mass spectrometry. Clin Chem. 2004; 50:224-226.
27. Lasker JM, Chen WB, Wolf I, et al. Formation of 20- hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney: role of Cyp4F2 and Cyp4A11. J Biol Chem. 2000;275:4118-4126.
28. De Caterina R. Endothelial dysfunctions: common denominators in vascular disease. Curr Opin Lipidol. 2000;11:9-23.
29. Nakagawa K, Marji JS, Schwartzman ML, et al. Androgen-mediated induction of the kidney arachidonate hydroxylases is associated with the development of hypertension. Am J Physiol. 2003;284:R1055-R1062.
30. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension. 2001;37:1199-1208.
31. Baron AD. Impaired glucose tolerance as a disease. Am J Cardiol 2001;88:16H-19H.
32. Keaney JF Jr, Larson MG, Vasan RS, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003;23:434-439.
33. Hoagland KM, Maier KG, Roman RJ. Contributions of 20-HETE to the antihypertensive effects of Tempol in Dahl salt-sensitive rats. Hypertens. 2003;41:697-702.
34. Schwartzman ML, Martasek P, Rios AR, et al. Cytochrome P450-dependent arachidonic acid metabolism in human kidney. Kidney Int. 1990;37:94-99.